- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- CODE OF CONDUCT
- Thank you
XVIVO Perfusion breaks new ground in Germany and Texas
XVIVO Perfusion’s XPS™ has been approved by FDA in the USA for the evaluation of marginal lungs before lung transplantation and has received a CE mark in Europe. XPS™ is used with good clinical results at leading clinics in the USA and there is already one at a clinic in Asia. In Europe, EVLP using STEEN Solution™ was previously done manually, in other words without XPS™. Access to XPS™ enables EVLP to be standardized and simplified. There is now great interest in XPS™ in both the USA and in Europe. Further university hospitals in Europe and the USA plan to start using EVLP (lung evaluation) combined with XPS™ and STEEN Solution™.
“The first XPS™ for Europe is an important milestone for XVIVO Perfusion and we are very pleased that Europe is now part of the expansion of EVLP using XPS™ and STEEN Solution™. This is a big step forward in being able to save more patients with terminal lung disease and give them a new life,” says Magnus Nilsson, CEO of XVIVO Perfusion.
February 4, 2015
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59, firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on February 4, 2015 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.